EA202192753A1 - Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме - Google Patents

Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме

Info

Publication number
EA202192753A1
EA202192753A1 EA202192753A EA202192753A EA202192753A1 EA 202192753 A1 EA202192753 A1 EA 202192753A1 EA 202192753 A EA202192753 A EA 202192753A EA 202192753 A EA202192753 A EA 202192753A EA 202192753 A1 EA202192753 A1 EA 202192753A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amorphous solid
plasma concentrations
increased efficiency
achieve therapeutic
therapeutic plasma
Prior art date
Application number
EA202192753A
Other languages
English (en)
Russian (ru)
Inventor
Роберт Дж. Гармис
Жакуан Калани Левонс
Джей Поома Редди
Кевин Дж. Стефански
Врушали М. Вакнис
Тереза М. Зимба
Аджай Саксена
Срикант Коравади Сридхар
Гаджегдра Сингх Чован
Шармиста Пал
Шабеерали Паттассери
Роопа Нарасимхамуртхи
Нарайян Свами Пандуранга
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202192753A1 publication Critical patent/EA202192753A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA202192753A 2019-04-11 2020-04-10 Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме EA202192753A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
EA202192753A1 true EA202192753A1 (ru) 2022-01-11

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192753A EA202192753A1 (ru) 2019-04-11 2020-04-10 Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
IL310894A (en) 2021-09-17 2024-04-01 Bristol Myers Squibb Co Milovacian for the prevention and treatment of thromboembolic disorders
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83812B (en) 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
MY172424A (en) * 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
NO2721243T3 (https=) 2014-10-01 2018-10-20
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
ES2791319T3 (es) 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
AR118650A1 (es) 2021-10-20
WO2020210629A1 (en) 2020-10-15
BR112021020257A2 (pt) 2021-12-07
TW202104228A (zh) 2021-02-01
AU2020271103B2 (en) 2026-01-08
MX2021012288A (es) 2021-11-12
IL287103A (en) 2021-12-01
AU2025279715A1 (en) 2026-01-15
MX2025011559A (es) 2025-11-03
JP2025131625A (ja) 2025-09-09
CN113924300A (zh) 2022-01-11
CA3132530A1 (en) 2020-10-15
US20260042761A1 (en) 2026-02-12
US20220144835A1 (en) 2022-05-12
CL2021002627A1 (es) 2022-05-06
EP3953355A1 (en) 2022-02-16
US12509461B2 (en) 2025-12-30
JP2022526656A (ja) 2022-05-25
CO2021015054A2 (es) 2021-11-19
SG11202111131VA (en) 2021-11-29
PE20212367A1 (es) 2021-12-21
KR20210151183A (ko) 2021-12-13

Similar Documents

Publication Publication Date Title
EA202192753A1 (ru) Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX385054B (es) Piridinas sustituidas con heteroarilo y metodos de uso.
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
EA201991349A1 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
PH12021500034A1 (en) Compounds useful in hiv therapy
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
MX386616B (es) Compuestos de carfilzomib pegilados.
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201990279A1 (ru) Гербицидные композиции, содержащие фенилпиримидины
EA200870497A1 (ru) Бензимидазольные модуляторы vr1
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
EA201000277A1 (ru) Соединения для лечения гепатита с